Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial
Authors:
- 20 February 2020
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (5) , 729-737
Abstract
INTRODUCTION: Beta-blockers are the mainstay agents for portal pressure reduction and to modestly reduce hepatic venous pressure gradient (HVPG). We studied whether addition of simvastatin to carvedilol in cirrhotic patients for primary prophylaxis improves the hemodynamic response. METHODS: Cirrhotic patients with esophageal varices and with baseline HVPG > 12 mm Hg were prospectively randomized for primary prophylaxis to receive either carvedilol (group A, n = 110) or carvedilol plus simvastatin (group B, n = 110). Primary objective was to compare hemodynamic response (HVPG reduction of ≥20% or P = 0.85). The degree of mean HVPG reduction (17.3% and 17.8%, respectively, P = 0.98) and hemodynamic response (odds ratio [OR]: 0.88; 95% confidence interval [CI]: 0.43–1.83, P = 0.74) was also not different between the groups. Patients who achieved target heart rate with no hypotensive episodes in either group showed better hemodynamic response (77.8% vs 59.2%, P = 0.04). Failure to achieve target heart rate (OR: 0.48; 95% CI: 0.22–1.06) and Child C cirrhosis (OR: 4.49; 95% CI: 1.20–16.8) predicted nonresponse. Three (3.7%) patients on simvastatin developed transient transaminitis and elevated creatine phosphokinase and improved with drug withdrawal. Two patients in each group bled (P = 0.99). Three patients and 1 patient, respectively, in group A and B died (P = 0.32), with sepsis being the cause of death. DISCUSSION: Addition of simvastatin to carvedilol for 3 months for primary prophylaxis of variceal bleeding does not improve hemodynamic response over carvedilol monotherapy. Simvastatin usage should be closely monitored for adverse effects in Child C cirrhotic patients.Keywords
This publication has 29 references indexed in Scilit:
- Carvedilol for Portal Hypertension in Patients With CirrhosisHepatology, 2010
- Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthaseHepatology, 2007
- Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic ReviewGastroenterology, 2006
- Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patientsDigestive and Liver Disease, 2005
- Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cellsLife Sciences, 2004
- Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosisHepatology, 2002
- Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosisHepatology, 1999
- The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substancesEuropean Journal of Biochemistry, 1993
- Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal VaricesNew England Journal of Medicine, 1991
- Prediction of the First Variceal Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal VaricesNew England Journal of Medicine, 1988